Key Takeaways:
Johnson & Johnson on Tuesday reported first-quarter adjusted earnings of $2.70 a share on revenue of $24.06 billion, narrowly beating analyst expectations and sending shares higher in premarket trading.
The results were driven by strong performance in the company's Innovative Medicine and Medical Technology divisions, validating its strategy after spinning off its consumer health arm last year.
The company raised its full-year guidance, signaling confidence in its growth trajectory. Shares advanced 1.2% in premarket trading following the announcement.
Sales in the Innovative Medicine unit, which includes the company's lucrative oncology portfolio, grew by more than 11 percent. The drugmaker's three multiple myeloma treatments—Darzalex, Tecvayli, and Carvykti—were significant contributors. Carvykti, a CAR-T cell therapy, achieved blockbuster status for the first time in 2025. The medical technology segment also saw robust growth, with sales increasing by 7.7 percent.
Looking ahead, Johnson & Johnson now expects full-year adjusted earnings of $11.45 to $11.65 a share, up from a prior range of $11.43 to $11.63. The company sees sales of between $100.3 billion and $101.3 billion, an increase from the earlier forecast of $100 billion to $101 billion.
Despite the positive results, the company continues to face legal challenges, with 74,360 lawsuits related to claims that its talcum-based baby powder was contaminated with asbestos. Johnson & Johnson has consistently maintained that its talc products are safe.
The guidance raise suggests management is confident in its growth trajectory, particularly within its oncology and medical technology segments. Investors will be watching for further updates on the talc litigation and the integration of recent acquisitions in the upcoming quarters.
This article is for informational purposes only and does not constitute investment advice.
